Skyhawk Therapeutics
Skyhawk is developing small molecule therapeutics that correct RNA expression.
Its proprietary technology enables the rational design of small molecules that target the RNA splicing process.
The company is currently developing drug candidates for cancer, neurological disorders and rare diseases.
Latest Skyhawk Therapeutics News & Features
13 May 2024
14 September 2021
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze